The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients
- PMID: 20074482
- DOI: 10.1177/039463200902200434
The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients
Abstract
Rheumatoid arthritis (RA), with a prevalence of 0.46%, is found in about 272,004 patients in Italy. The socioeconomic cost of rheumatoid arthritis in Italy in 2002 has been estimated at Euro 1,600 million. Cost-effectiveness evaluations have been based on the concept that, with treatment, patients will not progress to the next level(s) of disease severity or will take a longer time to progress, thus avoiding or delaying the high costs and low utility associated with more severe disease. Many cost-effective studies have been based on the variation of Health Assessment Questionnaire (HAQ) in clinical trials. The objective of this study is to perform a cost-effective analysis of 86 patients with rheumatoid arthritis in therapy with adalimumab 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice. The group of patients in therapy with adalimumab had also taken methotrexate, mean dose 12.4+/-2.5 mg/week (22 patients) or leflunomide 20 mg/day (16 patients). The group of patients in therapy with etanercept had also taken methotrexate, mean dose 11.7+/-2.6 mg/week (24 patients) or leflunomide 20 mg/day (24 patients). Incremental costs and QALYs (quality adjusted life years) gains are calculated compared with baseline, assuming that without biologic treatment patients would remain at the baseline level through the year. Conversion HAQ scores to utility were based on the Bansback algorithm. The results after two years showed: in the group methotrexate+adalimumab the QALY gained was 0.62+/-0.15 with a treatment cost of Euro 26,517.62 and a QALY/cost of Euro 42,521.13. In the group methotrexate + etanercept the QALY gained was 0.64+/-0.26 with a treatment cost of Euro 25,020.96 and a QALY/cost of Euro 39,171.76. The result of using etanercept in association with methotrexate is cost-effectiveness with a QALY gained under the acceptable threshold of Euro 50,000. These are important data for discussion from an economic point of view when we choose a biologic therapy for rheumatoid arthritis in clinical practice.
Similar articles
-
Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.J Med Econ. 2012;15(2):340-51. doi: 10.3111/13696998.2011.649327. Epub 2012 Jan 6. J Med Econ. 2012. PMID: 22168785
-
Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.Pharmacoeconomics. 2006;24(12):1221-32. doi: 10.2165/00019053-200624120-00006. Pharmacoeconomics. 2006. PMID: 17129076
-
Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.Rheumatol Int. 2017 Sep;37(9):1441-1452. doi: 10.1007/s00296-017-3736-z. Epub 2017 May 18. Rheumatol Int. 2017. PMID: 28523420
-
Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.J Manag Care Pharm. 2006 Sep;12(7):555-69. doi: 10.18553/jmcp.2006.12.7.555. J Manag Care Pharm. 2006. PMID: 16981801 Free PMC article. Review.
-
Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis.Expert Opin Pharmacother. 2004 Sep;5(9):1881-6. doi: 10.1517/14656566.5.9.1881. Expert Opin Pharmacother. 2004. PMID: 15330726 Review.
Cited by
-
Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review.Curr Rheumatol Rep. 2014 Oct;16(10):447. doi: 10.1007/s11926-014-0447-2. Curr Rheumatol Rep. 2014. PMID: 25182675
-
Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature.Int J Rheumatol. 2011;2011:845496. doi: 10.1155/2011/845496. Epub 2011 Nov 22. Int J Rheumatol. 2011. PMID: 22162693 Free PMC article.
-
Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis.Am Health Drug Benefits. 2013 Mar;6(2):126-36. Am Health Drug Benefits. 2013. PMID: 24991351 Free PMC article.
-
Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.Pharmacoeconomics. 2014 Feb;32(2):109-34. doi: 10.1007/s40273-013-0120-z. Pharmacoeconomics. 2014. PMID: 24338344
-
Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.Auto Immun Highlights. 2010 Nov 4;1(2):87-94. doi: 10.1007/s13317-010-0013-5. eCollection 2010 Nov. Auto Immun Highlights. 2010. PMID: 26000112 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical